2026-10

The Lancet Infectious Diseases (القضية : 10) (الحجم : 26)

Summary Background Enteric infectious diseases claim more than 1 million lives annually and are among the top ten causes of death in children younger than 5 years. Remarkable global investment has been dedicated to enteric infectious disease prevention and control; however, the shifting global health landscape is testing the continuance of progress. To evaluate the current status and guide future interventions, we present the latest epidemiological estimates of enteric infectious diseases from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 and assess progress towards the Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD) mortality target of fewer than 20 deaths per 100 000 children younger than 5 years by 2025. Methods We quantified the incidence, mortality, and disability-adjusted life-years (DALYs) of enteric infectious diseases by age, sex, and year across 204 countries and territories from 1990 to 2023. In GBD 2023, the following were considered under the category of enteric infectious diseases: diarrhoeal diseases, enteric fever (typhoid and paratyphoid), invasive non-typhoidal Salmonella spp (iNTS) infections, and other intestinal infectious diseases. We also examined 15 aetiologies contributing to diarrhoeal diseases. Incidence and prevalence were estimated with DisMod-MR (version 2.1), a Bayesian meta-regression tool, drawing on data from systematic reviews, population-based surveys, claims data, and hospital sources. Cause-specific mortality was modelled with Cause of Death Ensemble Modelling based on data from sources including vital registration, mortality surveillance, verbal autopsy, and minimally invasive tissue sampling. Years of life lost and years lived with disability were computed and combined to derive DALYs. For aetiology-specific estimation, population-attributable fractions (PAFs) for 15 pathogens were derived with a counterfactual framework. Point estimates and 95% uncertainty intervals (UIs) were generated from 250 draws from the posterior distribution. Findings In 2023, enteric infectious diseases resulted in an estimated 1·27 million (95% UI 0·963–1·68) deaths globally, declining from 3·69 million (3·04–4·56) in 1990. The global age-standardised mortality rate (ASMR) decreased from 74·1 (62·0–92·9) per 100 000 population to 16·4 (12·6–21·3) per 100 000 population during the same period. Diarrhoeal diseases accounted for most deaths in 2023 (1·11 million [0·811–1·54]), followed by enteric fever and iNTS. South Asia and sub-Saharan Africa remained the most affected regions in 2023, with 599 000 (441 000–882 000) and 501 000 (373 000–648 000) deaths due to enteric infectious diseases, respectively, predominantly from diarrhoeal disease. Rotavirus was the leading cause of all-age diarrhoeal disease deaths (PAF 16·3% [12·0–21·5]), followed by norovirus (10·2% [2·4–17·0]) and Shigella spp (9·3% [5·4–15·2]). Among children younger than 5 years, PAFs of deaths due to diarrhoeal diseases were 40·2% (32·5–48·5) for rotavirus, 24·0% (15·1–36·7) for Shigella spp, and 23·4% (13·7–34·3) for adenovirus. Across 204 countries and territories, 141 met the GAPPD mortality target in 2023. The driving aetiologies among countries that did not meet the target in 2023 varied slightly by GBD super-region, but the highest or second-highest number of deaths in children younger than 5 years were consistently attributed to rotavirus. Astrovirus and sapovirus, newly included in GBD 2023, were responsible for 24 600 (6290–49 000) and 18 800 (4650–44 400) deaths, respectively, in 2023, mainly in children younger than 5 years. Interpretation Our findings show that mortality and ASMRs of enteric infectious diseases declined substantially between 1990 and 2023. This decline is consistent with the expansion of public health measures and broader socioeconomic development. However, the burden in 2023 remains considerably high, with the highest mortality concentrated in sub-Saharan Africa and south Asia. Considering that more than a quarter of all countries had yet to meet the GAPPD mortality target in 2023, sustained efforts are needed to address the persistent burden in affected countries and to adapt to the changing global health landscape.

2026-09

THE LANCET Public Health (القضية : 9) (الحجم : 11)

Background WHO's Global Oral Health Action Plan (GOHAP) targets include a 10% relative reduction in the combined prevalence of main oral conditions by 2030. The first GOHAP evaluation was planned for 2023, with subsequent evaluations scheduled for 2026 and 2030. The aim of this systematic analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 was to evaluate global and regional progress (2019–23) towards this target and related complementary indicators. Methods Using modelled estimates from epidemiological surveys and registries in 204 countries and territories, we estimated the age-standardised prevalence of untreated caries in deciduous and permanent teeth, severe periodontitis, edentulism, other oral disorders and orofacial clefts, and the age-standardised incidence of lip and oral cavity cancer. Progress towards GOHAP targets was measured by comparing the percentage change from 2019 to 2023 in the above indicators against the stated GOHAP target of a 10% relative reduction. Findings Globally, the age-standardised prevalence of main oral conditions declined (−1·55% [95% uncertainty interval −2·32 to −0·82]) between 2019 and 2023, but global cases increased by 3·07% (2·32 to 3·75), from 3·62 billion (3·35 to 3·95) to 3·73 billion (3·45 to 4·06). Among complementary indicators, reductions in age-standardised prevalence were observed for untreated caries in permanent teeth (−1·99% [−2·49 to −1·40]) whereas the age-standardised incidence of lip and oral cavity cancer increased (8·35% [0·13 to 16·32]), as did the age-standardised prevalence of orofacial clefts (2·25% [0·77 to 3·83]). Progress was heterogeneous across GBD super-regions, with south Asia having the largest reductions in the age-standardised prevalence of main oral conditions (−3·34% [−4·95 to −1·80]) and untreated caries in deciduous teeth (−9·09% [−17·62 to −0·08]). Sub-Saharan Africa showed the largest increase in prevalent cases of main oral conditions (9·51% [8·09–10·94]) and age-standardised incidence of lip and oral cavity cancer (14·86% [1·19–32·45]). The high-income super-region had an increase in the age-standardised prevalence of main oral conditions (1·24% [0·56–1·96]) and untreated caries in deciduous teeth (9·21% [6·60–11·89]). Interpretation Our modelled estimates of global trends in the prevalence of oral conditions from 2019 to 2023 suggest that early progress is modest and, at the current pace, insufficient to meet the 2030 GOHAP targets. Accelerated, equity-focused prevention and integration of essential oral health-care services within primary care and universal health coverage are needed, alongside strengthened oral cancer control and congenital anomaly care

2026-07

Nutrients (القضية : 15) (الحجم : 18)

Background: Hepatic lipid metabolism disorder has been linked to a wide range of diseases. Aspalathin is a flavonoid enriched in rooibos tea and has shown capacity to protect against hyperlipidemia, oxidative stress and inflammation. In the current study, we investigated the functional role of aspalathin in regulating liver metabolism and gut microbiota in the context of a high-fat diet (HFD). Methods: Male mice were fed a control diet or HFD, then HFD-fed animals were treated with or without aspalathin-rich extract (ASE). Hepatic neutral lipids were detected using oil red O staining and a colorimetric assay. Expression of cholesterol metabolism-, lipogenesis- and fatty acid β-oxidation-associated genes was measured. Gut microbiota was analyzed using 16S rRNA sequencing and bioinformatic approaches. Results: HFD-fed mice had markedly higher levels of triglycerides and cholesteryl esters and downregulated expression of cholesterol metabolism-, transport- and lipogenesis-related genes in the liver. ASE administration counteracted HFD-induced effects. In addition, HFD altered the composition, diversity and metabolic pathways of the gut microbiota. The richness of beneficial bacteria, particularly the butyrate-producing bacteria, was significantly decreased. The altered metabolic pathways are involved in the metabolism of carbohydrates, lipids, amino acids and nucleotides, as well as mitochondrial function. ASE treatment reversed most of the alterations back to the characteristics of the control group. Conclusions: Our results demonstrated the potential of ASE improving liver lipid metabolism and gut microbiota in the scenario of a high-fat diet, providing insights into future studies on the mechanism of ASE regulating lipid metabolism disorder.

2026-07

JAMA (القضية : 8) (الحجم : 336)

IMPORTANCE Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C–related burden is critical for guiding prevention and treatment strategies. OBJECTIVES To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends. DESIGN, SETTING, AND POPULATION This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals. EXPOSURE Population-level LDL-C concentrations. MAIN OUTCOMES AND MEASURES Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C–attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals. RESULTS In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C–attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings. CONCLUSIONS AND RELEVANCE Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.

2026-05

THE LANCET NEUROLOGY (القضية : 5) (الحجم : 25)

Background Meningitis remains the leading infectious cause of neurological disabilities globally, disproportionately affecting children younger than 5 years and populations in the African meningitis belt. Whereas previous global estimates focused on ten pathogen categories, this study presents the most comprehensive analysis to date, assessing the meningitis burden attributable to 17 causative pathogens based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 framework. Methods GBD is a systematic, scientific effort aimed at quantifying the comparative magnitude of health loss caused by diseases, injuries, and risk factors across age groups, sexes, and geographical locations over time. We estimated meningitis mortality using the Cause of Death Ensemble model (CODEm) and morbidity using DisMod-MR 2.1, incorporating data from vital registration, verbal autopsy, surveillance, hospital data, and systematic reviews. Aetiology-specific estimates were generated with pathogen-linked case-fatality ratios and splined binomial regression models. Risk factor attribution was based on established risk–outcome pairs and population attributable fractions. Findings In 2023, there were 259 000 (95% uncertainty interval 202 000–335 000) global deaths and 2·54 million (2·20–2·93) incident cases of meningitis. Children younger than 5 years accounted for more than a third of deaths (86 600 [53 300–149 000]). Streptococcus pneumoniae, Neisseria meningitidis, non-polio enteroviruses, and other viruses were the leading causes of death, while non-polio enteroviruses caused the most cases. The four WHO-defined preventable meningitis pathogens of interest (S pneumoniae, N meningitidis, Haemophilus influenzae, and Group B streptococcus) contributed to 98 700 deaths (77 000–127 000) and 594 000 cases (514 000–686 000). Low birthweight, short gestation, and household air pollution were the top risk factors for meningitis-related mortality. Interpretation Although mortality and incidence have declined significantly since 1990, progress is insufficient to meet WHO 2030 targets. Despite marked progress in reducing bacterial meningitis via global vaccination campaigns, a substantial meningitis burden persists, attributable both to common pathogens such as S pneumoniae and N meningitidis and to emerging non-bacterial pathogens such as Candida spp and drug-resistant fungi. Achieving WHO goals will require sustained investment in surveillance, vaccination, maternal screening, and health-system strengthening, especially in high-burden settings

2026-05

NATURE scientific data (القضية : 1) (الحجم : 13)

Soil eukaryotes, including fungi, protists, plants, and animals, are central to biosphere functioning and resilience. The Global Standardised Soil Eukaryome Dataset (GloSED) is the first dataset encompassing the entire spectrum of soil eukaryotes, covering 4,063 sampling sites in 121 countries on all continents, revealing nearly one million operational taxonomic units. All samples were collected and analysed using a standardised protocol minimizing technical biases. Long-read sequencing of full-length ITS and 18S-V9 regions provide broad taxonomic coverage and high-resolution identification supported by specialist curation of “dark taxa”. A rigorous bioinformatic processing ensures against homopolymer errors, PCR-mediated chimeras, and index switching providing high data quality. The dataset is supported by raw sequences and an open-source containerised workflow for reproducible analyses. The samples are accompanied by land-cover description and directly measured soil pH, δ13C, δ15N, as well as P, K, Ca, Mg, and total C and N contents. GloSED is the first database that enables ecological and biogeographic studies of entire soil eukaryotic communities from local to global scales.

2026-04

THE LANCET INFECTIOUS DISEASES (القضية : 4) (الحجم : 26)

Lower respiratory infections (LRIs) remain the world's leading infectious cause of death. This analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides global, regional, and national estimates of LRI incidence, mortality, and disability-adjusted life-years (DALYs), with attribution to 26 pathogens, including 11 newly modelled pathogens, across 204 countries and territories from 1990 to 2023. With new data and revised modelling techniques, these estimates serve as an update and expansion to GBD 2021. Through these estimates, we also aimed to assess progress towards the 2025 Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD) target for pneumonia mortality in children younger than 5 years. Methods Mortality from LRIs, defined as physician-diagnosed pneumonia or bronchiolitis, was estimated using the Cause of Death Ensemble model with data from vital registration, verbal autopsy, surveillance, and minimally invasive tissue sampling. The Bayesian meta-regression tool DisMod-MR 2.1 was used to model overall morbidity due to LRIs. DALYs were calculated as the sum of years of life lost (YLLs) and years lived with disability (YLDs) for all locations, years, age groups, and sexes. We modelled pathogen-specific case-fatality ratios (CFRs) for each age group and location using splined binomial regression to create internally consistent estimates of incidence and mortality proportions attributable to viral, fungal, parasitic, and bacterial pathogens. Progress was assessed towards the GAPPD target of less than three deaths from pneumonia per 1000 livebirths, which is roughly equivalent to a mortality rate of less than 60 deaths per 100 000 children younger than 5 years. Findings In 2023, LRIs were responsible for 2·50 million (95% uncertainty interval [UI] 2·24–2·81) deaths and 98·7 million (87·7–112) DALYs, with children younger than 5 years and adults aged 70 years and older carrying the highest burden. LRI mortality in children younger than 5 years fell by 33·4% (10·4–47·4) since 2010, with a global mortality rate of 94·8 (75·6–116·4) per 100 000 person-years in 2023. Among adults aged 70 years and older, the burden remained substantial with only marginal declines since 2010. A mortality rate of less than 60 deaths per 100 000 for children younger than 5 years was met by 129 of the 204 modelled countries in 2023. At a super-regional level, sub-Saharan Africa had an aggregate mortality rate in children younger than 5 years (hereafter referred to as under-5 mortality rate) furthest from the GAPPD target. Streptococcus pneumoniae continued to account for the largest number of LRI deaths globally (634 000 [95% UI 565 000–721 000] deaths or 25·3% [24·5–26·1] of all LRI deaths), followed by Staphylococcus aureus (271 000 [243 000–298 000] deaths or 10·9% [10·3–11·3]), and Klebsiella pneumoniae (228 000 [204 000–261 000] deaths or 9·1% [8·8–9·5]). Among pathogens newly modelled in this study, non-tuberculous mycobacteria (responsible for 177 000 [95% UI 155 000–201 000] deaths) and Aspergillus spp (responsible for 67 800 [59 900–75 900] deaths) emerged as important contributors. Altogether, the 11 newly modelled pathogens accounted for approximately 22% of LRI deaths. Interpretation This comprehensive analysis underscores both the gains achieved through vaccination and the challenges that remain in controlling the LRI burden globally. Furthermore, it demonstrates persistent disparities in disease burden, with the highest mortality rates concentrated in countries in sub-Saharan Africa. Globally, as well as in these high-burden locations, the under-5 LRI mortality rate remains well above the GAPPD target. Progress towards this target requires equitable access to vaccines and preventive therapies—including newer interventions such as respiratory syncytial virus monoclonal antibodies—and health systems capable of early diagnosis and treatment. Expanding surveillance of emerging pathogens, strengthening adult immunisation programmes, and combating vaccine hesitancy are also crucial. As the global population ages, the dual challenge of sustaining gains in child survival while addressing the rising vulnerability in older adults will shape future pneumonia control strategies

2026-04

Science Journal of University of Zakho (القضية : 2) (الحجم : 14)

Diarrhea in children remains a significant global health burden and is closely linked to gut microbiota dysbiosis. However, data from Middle Eastern populations, particularly Iraq, remain limited. This study aims to characterize the change of gut microbiota associated with diarrhea in Iraqi children and to identify the potential of microbial imbalance by comparison with healthy controls. Stool samples were collected from 10 children (6 with diarrhea, 4 healthy controls) at Hevi Pediatric Teaching Hospital, Duhok, Iraq. Bacterial DNA was extracted and analyzed using 16S rRNA amplicon sequencing (V3–V4 region, Illumina NovaSeq). Sequence data were processed with QIIME2 software to assess taxonomic structure, α- and β-diversity. Comparisons between groups were performed using the Wilcoxon signed-rank test and the Metacoder Tree test. In this study, 241 bacterial taxa belonging to 11 phyla were identified. An enrichment in Proteobacteria and Bacteroidota was observed in cases of diarrhea, while the abundance of Firmicutes, alongside Ruminococcaceae, Lachnospiraceae, and Akkermansia muciniphila, was reduced. Notably, beneficial SCFA-producing genera, including Blautia, Faecalibacterium, and Bifidobacterium, were significantly reduced, while Enterobacteriaceae and Enterococcaceae were increased. Elevated ratios of Bacteroidota/Firmicutes and Proteobacteria/Firmicutes (p < 0.05) were also noted. Although no statistically significant differences were observed for α-diversity, β-diversity confirmed distinct clustering of both groups of diarrheal versus healthy microbiota. Diarrhea in Iraqi children was characterized by a shift of microbiome and a marked overgrowth of Proteobacteria, along with depletion of Firmicutes and loss of SCFA-producing genera, consistent with indicators of global microbial imbalance. However, the elevated Bacteroidota suggests region-specific indicators. These population-level variations may serve as biomarkers of imbalance. Further, larger, longitudinal, multi-omic studies are required to validate these findings.

2026-02

Letters in Applied Microbiology (القضية : 2) (الحجم : 79)

Burkholderia cepacia (B. cepacia) is Gram-negative, multidrug-resistant bacteria that can infect neonates and hospitalized patients, often spreading through contaminated medical devices. It causes various infections including sepsis, and it is difficult to treat due its antibiotic resistance. Over a three-year period (2021–2023), data from the ICU at Hevi Pediatric Teaching Hospital were reviewed and analyzed. Sepsis cases were identified based on clinical signs and confirmed through blood culture. B. cepacia identification and sensitivity test were confirmed using the VITEK system. Out of a total 1046 blood samples, 524 (50.1%) demonstrated positive bacterial growth, among which 142 (27.1%) identified as B. cepacia sepsis. The total neonatal cases counted for 123, 112 (91.1%) occurred in males and 11(8.9%) in females. Early-onset sepsis (EOS, ≤72 h) accounted for 49 cases (39.8%) and late-onset sepsis (LOS, > 72 h) for 74 (60.2%). The overall in-hospital mortality rate was 10.6% (13/123). Notably, B. cepacia isolates exhibited extensive multidrug resistance. Only a limited number of antimicrobials, including meropenem (3% resistance), ceftazidime (5%) and trimethoprim/sulfamethoxazole (9%) demonstrated promising results. These findings underscore an urgent need for coordinated interventions, emphasizing prudent antibiotic use and the strengthening of antimicrobial stewardship program to mitigate further resistance.

2026-02

The Lancet Infectious Diseases (القضية : 2) (الحجم : 2)

Background Tuberculosis (TB) is the leading global cause of death from a single infectious agent. Recent reductions in global health funding have threatened TB control, making comprehensive assessment of TB, HIV-related TB, and drug-resistant TB burdens before these disruptions essential for shaping effective responses. The WHO End TB Strategy sets targets of a 95% reduction in TB deaths and a 90% reduction in TB incidence between 2015 and 2035. Using results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023, this study aims to assess the burden of TB and multidrug-resistant TB (MDR-TB) across 204 countries and territories, and to evaluate progress towards the WHO End TB incidence and mortality targets. Methods We quantified TB mortality using the Cause of Death Ensemble modelling platform with global vital registration, surveillance, verbal autopsy, and minimally invasive tissue sampling data. For TB morbidity estimation, we simultaneously modelled incidence, prevalence, and mortality by age and sex using DisMod-MR 2.1. A population attributable fraction (PAF) approach was applied to stratify morbidity and mortality estimates by HIV and drug-resistance status. We also calculated disability-adjusted life-years (DALYs) as the sum of years of life lost and years lived with disability. For the risk factor analysis, a comparative risk assessment framework was used and PAFs were derived for alcohol use, smoking, and high fasting plasma glucose to determine the proportion of TB burden associated with these risk factors. Findings In 2023, there were an estimated 9·11 million (95% uncertainty interval 8·04–10·3) incident cases of all-form TB, 1·22 million (0·98–1·49) deaths, and 54·6 million (43·8–65·5) DALYs globally. HIV-related TB comprised 781 000 (690 000–879 000) incident cases and 210 000 (142 000–279 000) deaths, contributing 11·0 million (7·56–14·3) DALYs. MDR-TB accounted for 466 000 (198 000–1 080 000) incident cases, 102 000 (31 700–238 000) deaths, and 3·96 million (1·31–9·01) DALYs. From 2015 to 2023, global all-form TB incidence rates declined by 19·2% (17·8–20·5) and deaths declined by 22·6% (4·7–35·7); declines were larger for drug-susceptible TB than for MDR-TB. Sub-Saharan Africa and south Asia had the highest mortality burdens in 2023; reductions in all-form TB incidence and mortality were uneven between 2000 and 2023, with limited progress in both measures in Latin America and the Caribbean. Removing smoking, alcohol use, and high fasting plasma glucose would reduce global TB deaths to 768 000 (592 000–970 000) and DALYs to 34·9 million (27·8–43·8) in 2023; MDR-TB deaths would decrease to 77 200 (23 400–183 000) and DALYs to 3·12 million (1·03–7·29). Interpretation Global progress towards WHO End TB targets is disparate and fragile. Although many regions achieved meaningful gains, others have stagnated in recent years. The complexity of TB prevention is amplified by divergent MDR-TB trends, the persistent burden of HIV, and growing exposure to modifiable risk factors. Recent volatility in global health financing threatens to further destabilise this vulnerable epidemiological landscape; concerted action is urgently needed to temper disruptions and preserve progress.

2025-12

Journal of the American College of Cardiology (القضية : 22) (الحجم : 86)

BACKGROUND Cardiovascular diseases (CVDs) are the leading cause of mortality and are among the foremost causesof disability globally. CVD burden has continued to increase in most countries since 1990, with trends driven bychanging exposures to harmful risk factors, population growth, and population aging.OBJECTIVES We report estimates of global, national, and subnational CVD burden, including 18 subdiseases and12 associated modifiable risk factors. We analyzed change in CVD burden from 1990 to 2023 and identified drivers ofchange including population growth, population aging, and risk factor exposure.METHODS The Global Burden of Disease (GBD) 2023 study, a multinational collaborative research study, quantifiedburden due to 375 diseases including CVD burden and identified drivers of change from 1990 to 2023 using all availabledata and statistical models. GBD 2023 estimated the population-level burden of diseases in 204 countries and territoriesfrom 1990 to 2023.RESULTS CVDs were the leading cause of disability-adjusted life years (DALYs) and deaths estimated in the GBD. As of2023, there were 437 million (95% UI: 401 to 465 million) CVD DALYs globally, a 1.4-fold increase from the number in1990 of 320 million (292 to 344 million). Ischemic heart disease, intracerebral hemorrhage, ischemic stroke, and hy-pertensive heart disease were the leading cardiovascular causes of DALYs in 2023 globally. As of 2023, age-standardized CVD DALY rates were highest in low and low-middle Socio-demographic Index (SDI) settings and lowest inhigh SDI settings. The number of CVD deaths increased globally from 13.1 million (95% UI: 12.2 to 14.0 million) in 1990to 19.2 million (95% UI: 17.4 to 20.4 million) in 2023. The number of prevalent cases of CVD more than doubled since1990, with 311 million (95% UI: 294 to 333 million) prevalent cases of CVD in 1990 and 626 million (95% UI: 591 to 672million) prevalent cases in 2023 globally. A total of 79.6% (95% UI: 75.7% to 82.5%) of CVD burden is attributable tomodifiable risk factors 347 million [95% UI: 318 to 373 million] DALYs in 2023). Globally, high systolic blood pressure,dietary risks, high low-density lipoprotein cholesterol, and air pollution were the modifiable risks responsible for mostattributable CVD burden in 2023. Since 1990, changes in exposure to modifiable risk factors have had mixed effects onCVD burden, with increases in high body mass index, high fasting plasma glucose, and low physical activity leading tohigher burden, while reductions in tobacco usage have mitigated some of these increases. Population growth andpopulation aging were the main drivers of the increasing burden since 1990, adding 128 million (95% UI: 115 to 139million) and 139 million (95% UI: 126 to 151 million) CVD DALYs to the increase in CVD burden since 1990.CONCLUSIONS CVD remains the leading cause of disease burden and death worldwide with the greatest burden inlow, low-middle, and middle SDI regions. Large variation exists in CVD burden even for countries at similar levels ofdevelopment, a gap explained substantially by known, modifiable risk factors that are inadequately controlled. Thedecades-long increase in CVD burden was the result of population growth, population aging, and increased exposure to asubset of risk factors led by metabolic risks. Countries will need to adopt effective health system and public healthstrategies if they are to progress in achieving global goals to reduce the burden of CVD. (JACC. 2025;86:2167–2243)© 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an openaccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ISSN 0735-1097 https://doi.org/10.1016/j.jacc.2025.08.015Listen to this manuscript’saudio summary byEditor-in-ChiefDr Harlan M. Krumholz onwww.jacc.org/journal/jacc/podcasts.J A C C V O L . 8 6 , N O . 2 2 , 2 0 2 5© 2 0 2 5 T H E A U T H O R S . P U B L I S H E D B Y E L S E V I E R O N B E H A L F O F T H E A M E R I C A NC O L L E G E O F C A R D I O L O G Y F O U N D A T I O N . T H I S I S A N O P E N A C C E S S A R T I C L E U N D E RT H E C C B Y - N C - N D L I C E N S E ( h t t p : / / c r e a t i v e c o m m o n s . o r g / l i c e n s e s / b y - n c - n d / 4 . 0 / ) .

2025-10

THE LANCET (القضية : 10513) (الحجم : 406)

Summary Background Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides cause-specific mortality estimates measured in counts, rates, and years of life lost (YLLs). GBD 2023 aimed to enhance our understanding of the relationship between age and cause of death by quantifying the probability of dying before age 70 years (70q0) and the mean age at death by cause and sex. This study enables comparisons of the impact of causes of death over time, offering a deeper understanding of how these causes affect global populations. Methods GBD 2023 produced estimates for 292 causes of death disaggregated by age-sex-location-year in 204 countries and territories and 660 subnational locations for each year from 1990 until 2023. We used a modelling tool developed for GBD, the Cause of Death Ensemble model (CODEm), to estimate cause-specific death rates for most causes. We computed YLLs as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. Probability of death was calculated as the chance of dying from a given cause in a specific age period, for a specific population. Mean age at death was calculated by first assigning the midpoint age of each age group for every death, followed by computing the mean of all midpoint ages across all deaths attributed to a given cause. We used GBD death estimates to calculate the observed mean age at death and to model the expected mean age across causes, sexes, years, and locations. The expected mean age reflects the expected mean age at death for individuals within a population, based on global mortality rates and the population's age structure. Comparatively, the observed mean age represents the actual mean age at death, influenced by all factors unique to a location-specific population, including its age structure. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 250-draw distribution for each metric. Findings are reported as counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2023 include a correction for the misclassification of deaths due to COVID-19, updates to the method used to estimate COVID-19, and updates to the CODEm modelling framework. This analysis used 55 761 data sources, including vital registration and verbal autopsy data as well as data from surveys, censuses, surveillance systems, and cancer registries, among others. For GBD 2023, there were 312 new country-years of vital registration cause-of-death data, 3 country-years of surveillance data, 51 country-years of verbal autopsy data, and 144 country-years of other data types that were added to those used in previous GBD rounds. Findings The initial years of the COVID-19 pandemic caused shifts in long-standing rankings of the leading causes of global deaths: it ranked as the number one age-standardised cause of death at Level 3 of the GBD cause classification hierarchy in 2021. By 2023, COVID-19 dropped to the 20th place among the leading global causes, returning the rankings of the leading two causes to those typical across the time series (ie, ischaemic heart disease and stroke). While ischaemic heart disease and stroke persist as leading causes of death, there has been progress in reducing their age-standardised mortality rates globally. Four other leading causes have also shown large declines in global age-standardised mortality rates across the study period: diarrhoeal diseases, tuberculosis, stomach cancer, and measles. Other causes of death showed disparate patterns between sexes, notably for deaths from conflict and terrorism in some locations. A large reduction in age-standardised rates of YLLs occurred for neonatal disorders. Despite this, neonatal disorders remained the leading cause of global YLLs over the period studied, except in 2021, when COVID-19 was temporarily the leading cause. Compared to 1990, there has been a considerable reduction in total YLLs in many vaccine-preventable diseases, most notably diphtheria, pertussis, tetanus, and measles. In addition, this study quantified the mean age at death for all-cause mortality and cause-specific mortality and found noticeable variation by sex and location. The global all-cause mean age at death increased from 46·8 years (95% UI 46·6–47·0) in 1990 to 63·4 years (63·1–63·7) in 2023. For males, mean age increased from 45·4 years (45·1–45·7) to 61·2 years (60·7–61·6), and for females it increased from 48·5 years (48·1–48·8) to 65·9 years (65·5–66·3), from 1990 to 2023. The highest all-cause mean age at death in 2023 was found in the high-income super-region, where the mean age for females reached 80·9 years (80·9–81·0) and for males 74·8 years (74·8–74·9). By comparison, the lowest all-cause mean age at death occurred in sub-Saharan Africa, where it was 38·0 years (37·5–38·4) for females and 35·6 years (35·2–35·9) for males in 2023. Lastly, our study found that all-cause 70q0 decreased across each GBD super-region and region from 2000 to 2023, although with large variability between them. For females, we found that 70q0 notably increased from drug use disorders and conflict and terrorism. Leading causes that increased 70q0 for males also included drug use disorders, as well as diabetes. In sub-Saharan Africa, there was an increase in 70q0 for many non-communicable diseases (NCDs). Additionally, the mean age at death from NCDs was lower than the expected mean age at death for this super-region. By comparison, there was an increase in 70q0 for drug use disorders in the high-income super-region, which also had an observed mean age at death lower than the expected value. Interpretation We examined global mortality patterns over the past three decades, highlighting—with enhanced estimation methods—the impacts of major events such as the COVID-19 pandemic, in addition to broader trends such as increasing NCDs in low-income regions that reflect ongoing shifts in the global epidemiological transition. This study also delves into premature mortality patterns, exploring the interplay between age and causes of death and deepening our understanding of where targeted resources could be applied to further reduce preventable sources of mortality. We provide essential insights into global and regional health disparities, identifying locations in need of targeted interventions to address both communicable and non-communicable diseases. There is an ever-present need for strengthened health-care systems that are resilient to future pandemics and the shifting burden of disease, particularly among ageing populations in regions with high mortality rates. Robust estimates of causes of death are increasingly essential to inform health priorities and guide efforts toward achieving global health equity. The need for global collaboration to reduce preventable mortality is more important than ever, as shifting burdens of disease are affecting all nations, albeit at different paces and scales

2025-10

THE LANCET (القضية : 10513) (الحجم : 406)

Summary Background For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associated risk factors. This paper presents GBD 2023 findings on disease and injury burden and risk-attributable health loss, offering a global audit of the state of world health to inform public health priorities. This work captures the evolving landscape of health metrics across age groups, sexes, and locations, while reflecting on the remaining post-COVID-19 challenges to achieving our collective global health ambitions. Methods The GBD 2023 combined analysis estimated years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 375 diseases and injuries, and risk-attributable burden associated with 88 modifiable risk factors. Of the more than 310 000 total data sources used for all GBD 2023 (about 30% of which were new to this estimation round), more than 120 000 sources were used for estimation of disease and injury burden and 59 000 for risk factor estimation, and included vital registration systems, surveys, disease registries, and published scientific literature. Data were analysed using previously established modelling approaches, such as disease modelling meta-regression version 2.1 (DisMod-MR 2.1) and comparative risk assessment methods. Diseases and injuries were categorised into four levels on the basis of the established GBD cause hierarchy, as were risk factors using the GBD risk hierarchy. Estimates stratified by age, sex, location, and year from 1990 to 2023 were focused on disease-specific time trends over the 2010–23 period and presented as counts (to three significant figures) and age-standardised rates per 100 000 person-years (to one decimal place). For each measure, 95% uncertainty intervals [UIs] were calculated with the 2·5th and 97·5th percentile ordered values from a 250-draw distribution. Findings Total numbers of global DALYs grew 6·1% (95% UI 4·0–8·1), from 2·64 billion (2·46–2·86) in 2010 to 2·80 billion (2·57–3·08) in 2023, but age-standardised DALY rates, which account for population growth and ageing, decreased by 12·6% (11·0–14·1), revealing large long-term health improvements. Non-communicable diseases (NCDs) contributed 1·45 billion (1·31–1·61) global DALYs in 2010, increasing to 1·80 billion (1·63–2·03) in 2023, alongside a concurrent 4·1% (1·9–6·3) reduction in age-standardised rates. Based on DALY counts, the leading level 3 NCDs in 2023 were ischaemic heart disease (193 million [176–209] DALYs), stroke (157 million [141–172]), and diabetes (90·2 million [75·2–107]), with the largest increases in age-standardised rates since 2010 occurring for anxiety disorders (62·8% [34·0–107·5]), depressive disorders (26·3% [11·6–42·9]), and diabetes (14·9% [7·5–25·6]). Remarkable health gains were made for communicable, maternal, neonatal, and nutritional (CMNN) diseases, with DALYs falling from 874 million (837–917) in 2010 to 681 million (642–736) in 2023, and a 25·8% (22·6–28·7) reduction in age-standardised DALY rates. During the COVID-19 pandemic, DALYs due to CMNN diseases rose but returned to pre-pandemic levels by 2023. From 2010 to 2023, decreases in age-standardised rates for CMNN diseases were led by rate decreases of 49·1% (32·7–61·0) for diarrhoeal diseases, 42·9% (38·0–48·0) for HIV/AIDS, and 42·2% (23·6–56·6) for tuberculosis. Neonatal disorders and lower respiratory infections remained the leading level 3 CMNN causes globally in 2023, although both showed notable rate decreases from 2010, declining by 16·5% (10·6–22·0) and 24·8% (7·4–36·7), respectively. Injury-related age-standardised DALY rates decreased by 15·6% (10·7–19·8) over the same period. Differences in burden due to NCDs, CMNN diseases, and injuries persisted across age, sex, time, and location. Based on our risk analysis, nearly 50% (1·27 billion [1·18–1·38]) of the roughly 2·80 billion total global DALYs in 2023 were attributable to the 88 risk factors analysed in GBD. Globally, the five level 3 risk factors contributing the highest proportion of risk-attributable DALYs were high systolic blood pressure (SBP), particulate matter pollution, high fasting plasma glucose (FPG), smoking, and low birthweight and short gestation—with high SBP accounting for 8·4% (6·9–10·0) of total DALYs. Of the three overarching level 1 GBD risk factor categories—behavioural, metabolic, and environmental and occupational—risk-attributable DALYs rose between 2010 and 2023 only for metabolic risks, increasing by 30·7% (24·8–37·3); however, age-standardised DALY rates attributable to metabolic risks decreased by 6·7% (2·0–11·0) over the same period. For all but three of the 25 leading level 3 risk factors, age-standardised rates dropped between 2010 and 2023—eg, declining by 54·4% (38·7–65·3) for unsafe sanitation, 50·5% (33·3–63·1) for unsafe water source, and 45·2% (25·6–72·0) for no access to handwashing facility, and by 44·9% (37·3–53·5) for child growth failure. The three leading level 3 risk factors for which age-standardised attributable DALY rates rose were high BMI (10·5% [0·1 to 20·9]), drug use (8·4% [2·6 to 15·3]), and high FPG (6·2% [–2·7 to 15·6]; non-significant). Interpretation Our findings underscore the complex and dynamic nature of global health challenges. Since 2010, there have been large decreases in burden due to CMNN diseases and many environmental and behavioural risk factors, juxtaposed with sizeable increases in DALYs attributable to metabolic risk factors and NCDs in growing and ageing populations. This long-observed consequence of the global epidemiological transition was only temporarily interrupted by the COVID-19 pandemic. The substantially decreasing CMNN disease burden, despite the 2008 global financial crisis and pandemic-related disruptions, is one of the greatest collective public health successes known. However, these achievements are at risk of being reversed due to major cuts to development assistance for health globally, the effects of which will hit low-income countries with high burden the hardest. Without sustained investment in evidence-based interventions and policies, progress could stall or reverse, leading to widespread human costs and geopolitical instability. Moreover, the rising NCD burden necessitates intensified efforts to mitigate exposure to leading risk factors—eg, air pollution, smoking, and metabolic risks, such as high SBP, BMI, and FPG—including policies that promote food security, healthier diets, physical activity, and equitable and expanded access to potential treatments, such as GLP-1 receptor agonists. Decisive, coordinated action is needed to address long-standing yet growing health challenges, including depressive and anxiety disorders. Yet this can be only part of the solution. Our response to the NCD syndemic—the complex interaction of multiple health risks, social determinants, and systemic challenges—will define the future landscape of global health. To ensure human wellbeing, economic stability, and social equity, global action to sustain and advance health gains must prioritise reducing disparities by addressing socioeconomic and demographic determinants, ensuring equitable health-care access, tackling malnutrition, strengthening health systems, and improving vaccination coverage. We live in times of great opportunity.

2025-10

Front. Cell. Infect. Microbiol (القضية : 41245253) (الحجم : 15)

Background Age-related macular degeneration (AMD) is a common retinal disorder, causing blindness in aged individuals. One of the traditional Chinese medicines, modified Zhujing pill (MZP), has been widely used to treat various ocular disorders, including AMD; however, its protective mechanisms remain elusive. In this study, we explored the functional role of MZP in high-fat-diet-fed mice, a commonly used model for AMD. Methods Compounds of MZP water extract were identified by high-performance liquid chromatography (HPLC)/mass spectrometry (MS)/MS. The mice were divided into three groups: group 1 mice fed with control diet (CD), group 2 mice fed with high-fat diet (HFD), and group 3 mice fed with HFD for 12 weeks; groups 1 and 2 were then treated with physiological saline, while group 3 was treated with MZP for 4 weeks. The cholesterol level and expression of cholesterol homeostasis-associated genes, antioxidant genes, and proinflammatory cytokines in mouse tissues were measured using biochemical approaches. Mouse cecum microbiota compositions and metabolic functions were analyzed using 16rRNA sequencing and bioinformatics approach. Results HFD-fed mice had high levels of cholesterol in the retinal pigment epithelial (RPE) cells, liver, and serum, a decreased expression of cholesterol homeostasis-associated genes and antioxidant genes in the RPE and liver, and an increased expression of proinflammatory cytokines. MZP treatment counteracted HFD-induced pathologic effects. Additionally, HFD altered cecum bacterial compositions and diversities associated with individual metabolic pathways. These metabolic pathways are involved in the biosynthesis of bacterial metabolites, mitochondrial function, oxidative stress, and inflammation. MZP reversed most of the changes back to control characteristics. Conclusion We postulate that the beneficial effects of MZP against AMD are possibly related to lowering the cholesterol level, suppressing oxidative stress and inflammation, and modulating gut microbiota and associated functions.

2025-06

Pharmaceutical Research (القضية : 1790) (الحجم : 42)

Background Age-related macular degeneration (AMD) is the commonest cause of retinal disorders in the aged population. Ziyin-Mingmu decoction (ZD) has been widely used to treat AMD patients over thousands of years, however the underlying functional mechanisms of ZD are largely elusive. In this study, we aim to elucidate the therapeutic mechanisms of ZD in AMD models. Methods An in vivo AMD mouse model and an in vitro AMD model were established. Cholesterol level in mouse tissues was measured. Expression of antioxidant genes and proinflammatory cytokines in mouse tissues and in human retinal pigment epithelial (RPE) cells were detected using biochemical approaches. Gut microbiota community and functional pathways were analysed using bioinformatics approach. Compounds in ZD were identified using HPLC/MS. Results High fat diet (HFD)-fed mice had significantly higher levels of cholesterol in the retina, RPE, liver and serum, and markedly decreased expression of cholesterol metabolism-associated genes in those tissues, compared to mice fed with normal diet. Similarly, expression of antioxidant and inflammation genes was dysregulated in HFD-fed mouse tissues. ZD treatment reversed these HFD-induced pathological effects. HFD also altered the composition of cecum bacterial communities and associated metabolic pathways, which returned to control levels by ZD. In vitro assays showed that H2O2 significantly increased oxidative stress and enhanced expression of proinflammatory cytokines. Co-treatment with ZD significantly counteracted these changes. HPLC/MS identified 105 compound in water extracted ZD and most are polyphenols. Conclusion Our data suggests that protection of ZD against AMD is possibly through mitigating cholesterol level, oxidative stress and inflammation, and modulating gut microbiota by polyphenols.

2025-06

THE LANCET (القضية : 10500) (الحجم : 406)

Summary Background Since its inception in 1974, the Essential Programme on Immunization (EPI) has achieved remarkable success, averting the deaths of an estimated 154 million children worldwide through routine childhood vaccination. However, more recent decades have seen persistent coverage inequities and stagnating progress, which have been further amplified by the COVID-19 pandemic. In 2019, WHO set ambitious goals for improving vaccine coverage globally through the Immunization Agenda 2030 (IA2030). Now halfway through the decade, understanding past and recent coverage trends can help inform and reorient strategies for approaching these aims in the next 5 years. Methods Based on the Global Burden of Diseases, Injuries, and Risk Factors Study 2023, this study provides updated global, regional, and national estimates of routine childhood vaccine coverage from 1980 to 2023 for 204 countries and territories for 11 vaccine-dose combinations recommended by WHO for all children globally. Employing advanced modelling techniques, this analysis accounts for data biases and heterogeneity and integrates new methodologies to model vaccine scale-up and COVID-19 pandemic-related disruptions. To contextualise historic coverage trends and gains still needed to achieve the IA2030 coverage targets, we supplement these results with several secondary analyses: (1) we assess the effect of the COVID-19 pandemic on vaccine coverage; (2) we forecast coverage of select life-course vaccines up to 2030; and (3) we analyse progress needed to reduce the number of zero-dose children by half between 2023 and 2030. Findings Overall, global coverage for the original EPI vaccines against diphtheria, tetanus, and pertussis (first dose [DTP1] and third dose [DTP3]), measles (MCV1), polio (Pol3), and tuberculosis (BCG) nearly doubled from 1980 to 2023. However, this long-term trend masks recent challenges. Coverage gains slowed between 2010 and 2019 in many countries and territories, including declines in 21 of 36 high-income countries and territories for at least one of these vaccine doses (excluding BCG, which has been removed from routine immunisation schedules in some countries and territories). The COVID-19 pandemic exacerbated these challenges, with global rates for these vaccines declining sharply since 2020, and still not returning to pre-COVID-19 pandemic levels as of 2023. Coverage for newer vaccines developed and introduced in more recent years, such as immunisations against pneumococcal disease (PCV3) and rotavirus (complete series; RotaC) and a second dose of the measles vaccine (MCV2), saw continued increases globally during the COVID-19 pandemic due to ongoing introductions and scale-ups, but at slower rates than expected in the absence of the pandemic. Forecasts to 2030 for DTP3, PCV3, and MCV2 suggest that only DTP3 would reach the IA2030 target of 90% global coverage, and only under an optimistic scenario. The number of zero-dose children, proxied as children younger than 1 year who do not receive DTP1, decreased by 74·9% (95% uncertainty interval 72·1–77·3) globally between 1980 and 2019, with most of those declines reached during the 1980s and the 2000s. After 2019, counts of zero-dose children rose to a COVID 19-era peak of 18·6 million (17·6–20·0) in 2021. Most zero-dose children remain concentrated in conflict-affected regions and those with various constraints on resources available to put towards vaccination services, particularly sub-Saharan Africa. As of 2023, more than 50% of the 15·7 million (14·6–17·0) global zero-dose children resided in just eight countries (Nigeria, India, Democratic Republic of the Congo, Ethiopia, Somalia, Sudan, Indonesia, and Brazil), emphasising persistent inequities. Interpretation Our estimates of current vaccine coverage and forecasts to 2030 suggest that achieving IA2030 targets, such as halving zero-dose children compared with 2019 levels and reaching 90% global coverage for life-course vaccines DTP3, PCV3, and MCV2, will require accelerated progress. Substantial increases in coverage are necessary in many countries and territories, with those in sub-Saharan Africa and south Asia facing the greatest challenges. Recent declines will need to be reversed to restore previous coverage levels in Latin America and the Caribbean, especially for DTP1, DTP3, and Pol3. These findings underscore the crucial need for targeted, equitable immunisation strategies. Strengthening primary health-care systems, addressing vaccine misinformation and hesitancy, and adapting to local contexts are essential to advancing coverage. COVID-19 pandemic recovery efforts, such as WHO’s Big Catch-Up, as well as efforts to bolster routine services must prioritise reaching marginalised populations and target subnational geographies to regain lost ground and achieve global immunisation goals

2025-05

SSRN

Abstract Background Since its inception in 1974, the Expanded Programme on Immunization (EPI) has achieved remarkable success, averting the deaths of an estimated 154 million children worldwide through routine childhood vaccination. However, persistent coverage inequities and stagnating progress in recent decades have been further amplified by the COVID-19 pandemic. Methods This study provides updated global, regional, and national estimates of routine childhood vaccine coverage from 1980 to 2023 for 204 countries and territories, comprehensive assessment of the pandemic’s impact on coverage, and forecasts to 2030. Employing advanced modelling techniques, this analysis accounts for data biases and heterogeneity and integrates new methodologies to model vaccine scale-up and pandemic-related disruptions. Findings Global coverage for original EPI vaccines against diphtheria-tetanus-pertussis (DTP1 and DTP3, ie, first and third doses), measles (MCV1), polio (Pol3), and tuberculosis (BCG) nearly doubled from 1980 to 2023. However, coverage gains slowed between 2010 and 2019 in many countries, including declines in 23 of 36 high-income countries for at least one of these vaccine-doses. The COVID-19 pandemic exacerbated these challenges, with global rates for these vaccines declining sharply since 2020, and still not returning to pre-pandemic levels as of 2023. Coverage for newer vaccines, such as immunisations against pneumococcal disease (PCV3) and rotavirus (complete series, RotaC), saw continued increases globally during the pandemic due to ongoing introductions and scale-ups, but at slower rates than expected in the absence of COVID-19. Forecasts to 2030 for DTP3, PCV3 and MCV2 suggest that only DTP3 would reach 90% global coverage, and only under an optimistic scenario. The number of “zero-dose children”—those presumed not to have received a single vaccine dose—fell by 74·9% (95% uncertainty interval [UI] 72·1–77·3) globally between 1980 and 2019, but rose during the pandemic, remaining concentrated in conflict-affected, under-resourced regions, particularly sub-Saharan Africa. As of 2023, more than 50% of zero-dose children resided in just eight countries, emphasising persistent inequities. Interpretation Our estimates of current vaccine coverage and forecasts to 2030 suggest that achieving Immunization Agenda 2030 (IA2030) targets, such as halving zero-dose children compared to 2019 levels and reaching 90% global coverage for life-course vaccines DTP3, PCV3, and MCV2, will require accelerated progress. Substantial increases in coverage are necessary in many countries, with those in sub-Saharan Africa and south Asia facing the greatest challenges. Recovery to past coverage levels will be necessary in Latin America and Caribbean. These findings underscore the critical need for targeted, equitable immunisation strategies. Strengthening primary health-care systems, addressing vaccine misinformation, and adapting to local contexts are essential to advancing coverage. Pandemic recovery efforts, such as WHO’s “Big Catch-Up” initiative, must prioritise vulnerable populations and target subnational geographies to regain lost ground and achieve global immunisation goals.

2025-01

Microbiology Research MDPI (القضية : 20367481) (الحجم : 16)

Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, and is a significant contributor to both morbidity and mortality rates. Emerging research has promptly highlighted the potential role of the gut microbiome in the development and progression of CRC. This study aims to investigate the differences in gut microbiota between CRC patients and healthy individuals in Iraq, using 16S rRNA metagenomic sequencing on Illumina NovaSeq (PE250-Seq). A total of 21 stool samples were analyzed: 12 from early-stage CRC patients and nine from healthy controls. Bacterial DNA was extracted, followed by 16S rRNA amplicon sequencing to profile the microbial communities. The results indicated significant differences between the fecal microbiome of the two groups. Remarkably, CRC patients exhibited a marked reduction in Bacteroidota and an increase in Verrucomicrobiota compared to healthy controls. At the genus level, Prevotella, Faecalibacterium, Roseburia, Barnesiella, Eubacterium Lachnospiraceae_UCG_004, and Lachnospira were significantly less abundant in CRC patients compared to the healthy individuals, while Actinomyces, Monoglobus, Desulfovibrio, Akkermansia, and Bacteroides were highly enriched. In addition, diversity analyses further indicated decreased α-diversity and distinct β-diversity patterns in the CRC patients, suggesting significant shifts in the gut microbial composition. These findings underscore the potential of microbiome-based diagnostics and therapeutic strategies, with microbial alterations serving as biomarkers for CRC diagnosis. Further research needs to focus on elucidating the causal relationships and therapeutic potential of these microbiome changes in CRC management.

2025-01

Microbiology Research (القضية : 1) (الحجم : 16)

Abstract: Colorectal cancer (CRC) is the third most commonly diagnosed cancer globally, and is a significant contributor to both morbidity and mortality rates. Emerging research has promptly highlighted the potential role of the gut microbiome in the development and progression of CRC. This study aims to investigate the differences in gut microbiota between CRC patients and healthy individuals in Iraq, using 16S rRNA metagenomic sequencing on Illumina NovaSeq (PE250-Seq). A total of 21 stool samples were analyzed: 12 from early-stage CRC patients and nine from healthy controls. Bacterial DNA was extracted, followed by 16S rRNA amplicon sequencing to profile the microbial communities. The results indicated significant differences between the fecal microbiome of the two groups. Remarkably, CRC patients exhibited a marked reduction in Bacteroidota and an increase in Verrucomicrobiota compared to healthy controls. At the genus level, Prevotella, Faecalibacterium, Roseburia, Barnesiella, Eubacterium Lachnospiraceae_UCG_004, and Lachnospira were significantly less abundant in CRC patients compared to the healthy individuals, while Actinomyces, Monoglobus, Desulfovibrio, Akkermansia, and Bacteroides were highly enriched. In addition, diversity analyses further indicated decreased α-diversity and distinct β-diversity patterns in the CRC patients, suggesting significant shifts in the gut microbial composition. These findings underscore the potential of microbiome-based diagnostics and therapeutic strategies, with microbial alterations serving as biomarkers for CRC diagnosis. Further research needs to focus on elucidating the causal relationships and therapeutic potential of these microbiome changes in CRC management.

2024-11

CUREUS (القضية : 21688184) (الحجم : 11)

Helicobacter pylori (H. pylori) is a globally prevalent bacterium, infecting roughly half the global population, with higher prevalence rates in developing countries. This study aimed to investigate the prevalence of H. pylori among symptomatic dyspeptic patients in Zakho City, Iraq, evaluate its association with various risk factors, as well as evaluate the effectiveness of treatment in curing this bacterium. Of a total of 150 dyspeptic patients, 50 who had received antibiotics were excluded, leaving 100 patients without antibiotics enrolled in this study. These participants, aged 11-67 years, visited the private Nawroz Laboratory in Zakho City, Kurdistan, Iraq, between June 2021 and October 2022. These patients were tested using the Helicoprobe 14C-Urea breath test and data on various factors, including age, gender, smoking, family size, drinking water source, education level, BMI, hemoglobin levels, and blood group, were collected through structured interviews. In this study, the prevalence of this bacterium was 50%, with no significant difference observed between males and females as well as BMI, smoking, source of drinking water, and blood groups while significant associations were found between infection and increasing age, low Hb levels, and educational level. Notably, 46.7% of patients failed to respond to standard triple therapy, possibly due to antibiotic resistance. The ineffectiveness of standard triple therapy for H. pylori highlights the need for tailored treatments based on local antibiotic resistance patterns to improve prevention and treatment strategies with further investigation studies

2024-05

J Am Coll Cardiol. A (القضية : 82) (الحجم : 25)

Age-standardized CVD mortality rates by region ranged from 73.6 per 100,000 in High-income Asia Pacific to 432.3 per 100,000 in Eastern Europe in 2022. Global CVD mortality decreased by 34.9% from 1990 to 2022. Ischemic heart disease had the highest global age-standardized DALYs of all diseases at 2,275.9 per 100,000. Intracerebral hemorrhage and ischemic stroke were the next highest CVD causes for age-standardized DALYs. Age-standardized CVD prevalence ranged from 5,881.0 per 100,000 in South Asia to 11,342.6 per 100,000 in Central Asia. High systolic blood pressure accounted for the largest number of attributable age-standardized CVD DALYs at 2,564.9 per 100,000 globally. Of all risks, household air pollution from solid fuels had the largest change in attributable age-standardized DALYs from 1990 to 2022 with a 65.1% decrease.

2024-01

Front. Pharmacol. (القضية : 15) (الحجم : 15)

Sepsis is a life-threating complication among pediatric patients. This study aims primarily to investigate sepsis causative bacteria, their antimicrobial resistance profile, and to check the change of antimicrobial resistance trend for some selected bacteria.In addition, to evaluate the incidence of sepsis and related mortality rate. Besides, to evaluate the effectiveness and outcome of the treatment regimes in sepsis pediatric patients. A retrospective analysis was conducted on a four-year data (2018)(2019)(2020)(2021) collected from three Intensive Care Units of Hevi Pediatric Teaching Hospital. Sepsis screening involved clinical detection and confirmed by blood culture. A total of 520 out of 1098 (47.35%) blood samples showed positive microbial growth. Sepsis rate's reduction noticed during COVID-19 pandemic period. Coagulase-Negative Staphylococci (CoNS) and Klebsiella pneumonia were the most common isolated bacteria. A notable variation of antimicrobial resistance trend observed among sepsis causing bacteria. Obviously, the sepsis empirical treatment recommended by WHO was ineffective, as certain bacteria exhibited 100% resistance to every antibiotic tested. The mortality rate significantly increased from 1.3% in 2018 to 16.5% in 2021.The antimicrobial resistance profile for sepsis causing bacteria sending an alarm for expecting the worst. Thus, to avoid treatment failure, it is essential to monitor antimicrobial resistance in pediatric patient.

2023-12

Journal of the American College of Cardiology (القضية : 23502473) (الحجم : 82)

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) is a multinational collaborative research study with >10,000 collaborators around the world. GBD generates a time series of summary measures of health, including prevalence, cause-specific mortality (CSMR), years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life years (DALYs) to provide a comprehensive view of health burden for a wide range of stakeholders including clinicians, public and private health systems, ministries of health, and other policymakers. These estimates are produced for 371 causes of death and 88 risk factors according to mutually exclusive, collectively exhaustive hierarchies of health conditions and risks. The study is led by a principal investigator and governed by a study protocol, with oversight from a Scientific Council, and an Independent Advisory Committee.1 GBD is performed in compliance with Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).2 GBD uses de-identified data, and the waiver of informed consent was reviewed and approved by the University of Washington Institutional Review Board (study number 9060).

2023-09

Frontiers in Immunology (القضية : 1274401) (الحجم : 14)

Traditional Chinese Medicine (TCM) has been used for thousands of years but without any sound empirical basis. One TCM preparation is the Qijudihuang pill (QP), a mixture of eight herbs, which has been used in China for the treatment of various conditions including age-related macular degeneration (AMD), the most common cause of blindness in the elderly population. In order to explain the mechanism behind the effect of QP, we used an AMD model of high-fat diet (HFD) fed mice to investigate cholesterol homeostasis, oxidative stress, inflammation, and gut microbiota. Cholesterol levels in the retina, retinal pigment epithelium (RPE), liver, and serum were determined as was the expression of enzymes involved in cholesterol metabolism, inflammation, and oxidative stress. In the majority of the lipid determinations, analytes were elevated by HFD but this was reversed by QP. Cholesterol metabolism, including the enzymes of bile acid (BA) formation, was suppressed by HFD but again this was reversed by QP. Bas play a major role in signaling between host and microbiome and this is disrupted by HFDs, resulting in major changes in the composition of colonic bacterial communities. Associated with these changes are predictions of the metabolic pathway complexity and abundance of individual pathways. These concerned substrate breakdowns, energy production, and the biosynthesis of pro-inflammatory factors but were changed back to control characteristics by QP. We propose that the ability of QP to reverse these effects is related to mechanisms acting to lower cholesterol levels, oxidative stress, and inflammation and those that modulate gut microbiota.

2023-03

SJUOZ (القضية : 2663) (الحجم : 11)

ABSTRACT The prevalence of Staphylococcus aureus (S. aureus) among patients with urinary tract infections (UTIs) has become a significant cause of morbidity in all age groups. The aim of the current study was to identify S. aureus with methicillin-resistant S. aureus (MRSA). Moreover, it aimed to determine their antimicrobial susceptibility patterns and to detect the presence of the mecA, lukPV and icaA genes in isolated S. aureus among UTIs patients. A total of 402 urine samples were collected from patients diagnosed with UTIs aged (less than 80 years) at Zakho General Hospital in Zakho City, from August 2021 to March 2022. From these samples, a total of 37 (12.6%) S. aureus was identified and molecularly confirmed by the nuc gene. A high prevalence of MRSA 28 (75.7%) was identified from these isolates S. aureus by Oxacillin sensitive test and confirmed by mecA gene. Females were highly infected with UTIs than males, and most cases were in chronic condition and married. In addition, 18 (64.3%) and 21 (75%) of these isolates S. aureus were harbored luk-PV and icaA genes, respectively. There were widespread of antimicrobial resistance patterns for these bacteria. Isolated MRSA were highly sensitive to Imipenem. Interestingly, a significant positive correlation between mecA and both virulence marker genes (luk-PV and icaA) found in MRSA with UTIs. Conclusion, the data demonstrated, for the first time, alarming emergence of multidrug-resistant MRSA isolated from UTIs of community-acquired in Kurdistan Region-Iraq. Further studies are required in other cities to report whether or not MRSA is the cause of UTI patients in Iraqi Kurdistan.

2022-09

Antibiotics (القضية : 11) (الحجم : 14)

Background: The presence of extended-spectrum β-lactamase (ESBL)-producing bacteria among uropathogens is significantly increasing in children all over the world. Thus, this research was conducted to investigate the prevalence of E. coli and their antimicrobial susceptibility pattern, and both genes of ESBL-producing E. coli resistant and virulence factor in UTIs patients among children in Duhok Province, Kurdistan, Iraq. Method: a total of 67 E. coli were identified from 260 urine samples of pediatric patients diagnosed with UTIs aged (0–15 years) which were collected from Heevi Pediatric Teaching Hospital, from August 2021 to the end of February 2022. Result: a high proportion of UPEC infections at ages <5 years and the rates among girls (88%) were significantly higher than those among the boys. A wide variety of E. coli are resistant to most antibiotics, such as Amoxicillin, Ampicillin and Tetracycline, and 64% of them were positive for ESBL. Interestingly, the presence of both the ESBL marker genes (blaTEM, and blaCTX-M) as well as both virulence marker genes (pai and hly) were detected in above 90% of E. coli. Conclusion: the data illustrate an alarming increase in UPEC with ESBL production and the emergence of multidrug-resistant drugs in the early age of children. The public health sectors should further monitor the guidelines of using antibiotics in Kurdistan, Iraq.

2022-03

Bioscience of Microbiota, Food and Health, 2022 (القضية : 25.2022) (الحجم : 2021.075)

Dysbiosis of gut microbiota has adverse effects on host health. This study aimed to determine the effects of changes of faecal microbiota in obese and diabetic rats on the imputed production of enzymes involved in the metabolism of glutamate, gamma-aminobutyric acid (GABA), and succinate. The levels of glutamate decarboxylase, GABA transaminase, succinate-semialdehyde dehydrogenase, and methylisocitrate lyase were reduced or absent in diabetic rats compared with controls and obese rats. Glutamate decarboxylase (GAD) was significantly reduced in obese rats compared with control rats, while the other enzymes were unaltered; different bacterial taxa are suggested to be involved. Levels of bacterial enzymes were inversely correlated with the blood glucose level. These findings suggest that the absence of GABA and reduced succinate metabolism from gut microbiota contribute to the diabetic state in rats.

2021-12

Advances in Animal and Veterinary Sciences (القضية : 1) (الحجم : 10)

This research aimed to find out the prevalence of theileriosis by Giemsa stained blood films and to deal with hemato-biochemical changes in naturally infected cattle. The overall prevalence rates were 32.75% (95/290) for Theileria infection by Giemsa stained blood smears. Clinical examination of infected cattle showed signs of fever, anorexia, congested mucous membranes, corneal opacity, emaciation, enlargement of superficial lymph nodes, pale mucous membrane, respiratory signs, yellowish diarrhea and brown coffee urine were common clinical findings. There was no significant difference associated with prevalence between gender and age (P < 0.05). The hematological parameter revealed the microcytic anemia which was associated with large reductions in RBCs (4.48±0.11) 1012/l, Hb (7.15±0.18) g/dl, PCV (17.63±0.40) %, MCV (39.69±0.58) fl, MCHC (36.98±0.67) g/l and neutrophils (3.21±0.203) %. While a significant increase in the WBCs (13.24±0.32)109 /l and lymphocytes (61.42±1.84) % were found. The biochemical parameter revealed a significant increase in active serum enzyme AST (87.60± 0.12), ALT (21.70±0.07), ALP (119±0.06), and total serum bilirubin (1.13±0.01); whereas, a significant decrease in the total serum protein (6.10±0.03), albumin (2.70±0.03), calcium (7.40±0.02) and glucose (19.9±0.05) were recorded. According to the findings of this study, bovine theileriosis is a serious infectious disease in Erbil province. A more effective control program should be created to confine and manage the disease’s prevalence in the area.

2021-05

Experimental Eye Research (القضية : 108625) (الحجم : 208)

Age-related Macular Degeneration (AMD) is a major cause of sight impairment in the elderly with complex aetiology involving genetics and environment and with limited therapeutic options which have limited efficacy. We have previously shown in a mouse-model of the condition, induced by feeding a high fat diet, that adverse effects of the diet can be reversed by co-administration of the TSPO activator, etifoxine. We extend those observations showing improvements in retinal pigment epithelial (RPE) cells with decreased lipids and enhanced expression of cholesterol metabolism and transport enzymes. Further, etifoxine decreased levels of reactive oxygen species (ROS) in RPE and inflammatory cytokines in RPE and serum. With respect to gut microbiome, we found that organisms abundant in the high fat condition (e.g. in the genus Anaerotruncus and Oscillospira) and implicated in AMD, were much less abundant after etifoxine treatment. The changes in gut flora were associated with the predicted production of metabolites of benefit to the retina including tryptophan and other amino acids and taurine, an essential component of the retina necessary to counteract ROS. These novel observations strengthen earlier conclusions that the mechanisms behind improvements in etifoxine-induced retinal physiology involve an interaction between effects on the host and the gut microbiome.

2021-02

Environmental Pollution (الحجم : 270)

Although many pharmaceutical compounds (and their metabolites) can induce harmful impacts at the molecular, physiological and behavioural levels, their underlying mechanistic associations have remained largely unexplored. Here, we utilized RNA-Seq to build a whole brain transcriptome profile to examine the impact of a common endocrine disrupting pharmaceutical (17α-ethinyl estradiol, EE2) on reproductive behaviour in wild guppies (Poecilia reticulata). Specifically, we annotated 16,791 coding transcripts in whole brain tissue in relation to the courtship behaviour (i.e. sigmoid display) of EE2 exposed (at environmentally relevant concentration of 8 ng/L for 28-days) and unexposed guppies. Further, we obtained 10,960 assembled transcripts matching in the non-coding orthologous genomes. Behavioural responses were assessed using a standard mate choice experiment, which allowed us to disentangle chemical cues from visual cues. We found that a high proportion of the RNAseq reads aligned back to our de novo assembled transcriptome with 80.59% mapping rate. Behavioural experiments showed that when males were presented only with female visual cues, there was a significant interaction between male treatment and female treatment in the time spent in the preference zone. This is one of the first studies to show that transcriptome-wide changes are associated with the reproductive behaviour of fish: EE2 exposed male guppies that performed high levels of courtship had a gene profile that deviated the most from the other treatment groups, while both non-courting EE2 and control males had similar gene signatures. Using Gene Ontology pathway analysis, our study shows that EE2-exposed males had gene transcripts enriched for pathways associated with altered immunity, starvation, altered metabolism and spermatogenesis. Our study demonstrates that multiple gene networks orchestrate courting behaviour, emphasizing the importance of investigating impacts of pharmaceuticals on gene networks instead of single genes.

2021-01

Bioscience of Microbiota, Food and Health. (الحجم : 40)

Various studies have suggested that the gut microbiome interacts with the host and may have a significant role in the aetiology of obesity and Type 2 Diabetes (T2D). It was hypothesised that bacterial communities in obesity and T2D differ from control and compromise normal interactions between host and microbiota. Obesity and T2D were developed in rats by feeding a high-fat diet or a high-fat diet plus a single low-dose streptozotocin administration, respectively. The microbiome profiles and their metabolic potentials were established by metagenomic 16S rRNA sequencing and bioinformatics. Taxonomy and predicted metabolism-related genes in obesity and T2D were markedly different from controls and indeed from each other. Diversity was reduced in T2D but not in Obese rats. Factors likely to compromise host intestinal, barrier integrity were found in Obese and T2D rats including predicted, decreased bacterial butyrate production. Capacity to increase energy extraction via ABC-transporters and carbohydrate metabolism were enhanced in Obese and T2D rats. T2D was characterized by increased proinflammatory molecules. While obesity and T2D show distinct differences, results suggest that in both conditions Bacteroides and Blautia species were increased indicating a possible mechanistic link.

2020-10

Biochemical Pharmacology (الحجم : 180)

Obesity is intimately associated with diet and dysbiosis of gut microorganisms but anxiolytics, widely used in treatment of psychiatric conditions, frequently result in weight gain and associated metabolic disorders. We are interested in effects of the anxiolytic etifoxine, which has not been studied with respect to weight gain or effects on gut microorganisms. Here we induced obesity in mice by feeding a high-fat diet but found that intraperitoneal administration of etifoxine resulted in weight loss and decreased serum cholesterol and triglycerides. Obese mice had increased hepatic transcripts associated with lipid metabolism (cyp7a1, cyp27a1, abcg1 and LXRα) and inflammatory factors (TNFα and IL18) but these effects were reversed after etifoxine treatment other than cyp7a1. Taxonomic profiles of the organisms from the caecum were generated by 16S rRNA gene sequencing and Obese and etifoxine mice show differences by diversity metrics, Differential Abundance and functional metagenomics. Organisms in genus Oscillospira and genera from Lachnospiraceae family and Clostridiales order are higher in Control than Obese and at intermediate levels with etifoxine treatment. With respect to community metabolic potential, etifoxine mice have characteristics similar to Control and particularly with respect to metabolism of butanoate, sphingolipid, lipid biosynthesis and xenobiotic metabolism. We suggest mechanisms where-by etifoxine influences processes of host, such as on bile acid synthesis, and microbiota, such as signalling from production of butanoate and sphingosine, resulting in decreased cholesterol, lipids and inflammatory factors. We speculate that the indirect effect of etifoxine on microbial composition is mediated by microbial β-glucuronidases that metabolise excreted etifoxine glucuronides.

2013-12

Journal of Agriculture and Veterinary Science, (الحجم : 6)

A total of 41 sorbitol non fermentative E. coli from previous work were used in this study. Among these isolates 5 were positive serologically by anti-O157 serum. All isolates were tested by PCR technique. No E. coli O157 were detected in all isolates by PCR. The results revealed that gene based method such as PCR technique is more reliable than biochemical and serological tests for diagnosis of E. coli O157

2013-09

Journal of University of Zakho (JUOZ) (القضية : 1) (الحجم : 1)

This study was carried out for the first time to investigate the occurrence of E. coliO157 in sheep and goats in Duhok province, Iraq. A total of 320 samples were collected from April to July2009 as following: 100 fecal samples from sheep, 100 fecal samples from goats, 60 samples from sheep milk and 60 samples from goat milk. E coliO157 was isolated from 3 (3%) sheep fecal samples and 2 (2%) from goat fecal samples, while no E. coliO157 was detected in the milk samples from sheep and goats. E. coliO157 was detected only among E. coli isolates which were sorbitol non fermentative but MUG positive, while no E. coliO157 was detected among E. coli isolates which were negative for both sorbitol and MUG. All E. coliO157 isolates were resistant to 6 among 12 antimicrobial agents used in vitro drug sensitivity test.

2013-07

Research Opinions in Animal & Veterinary Sciences, (القضية : 1) (الحجم : 3)

This study was conducted to determine the prevalence of Salmonella species in slaughtered animals and abattoir sewage from Zakho Abattoir, Kurdistan Region, Iraq. A total of 500 samples were collected including 200 from healthy sheep (100 rectal swabs and 100 gallbladder contents), 100 from healthy goats (50 rectal swabs and 50 gallbladder contents), 100 from cattle (50 rectal swabs and 50 gallbladder contents), and 100 sewage samples from the abattoir drains. From the total of 400 animals examined, 9 (2.25%) were positive for Salmonella spp., in which 5 (2.5%) were from sheep [ 2 (2%) from rectal swabs and 3 (3%) from gallbladder], 2 (2%) were from rectal swabs of goats, and 2 (2%) were from cattle [1 (2%) from rectal swabs and 1 (2%) from gallbladder]. Whereas, only 3 (3%) were positive for Salmonella spp., obtained from 100 sewage samples. Only three serotypes of Salmonella were detected in 12 (2.4%) samples from the total 500 samples. The isolated Salmonella serotypes were Salmonella hato 8 (66.66%), Salmonella anatum 3 (25%), and Salmonella enteritidis 1 (8.33%). The antimicrobial sensitivity test of all 12 isolates against 13 antibiotics was studied. Results revealed that all isolates were 100% sensitive to amoxicillin, amikacin, gentamicin, and ciprofloxacin, and 100% resistant to clindamycin, rifampin, vancomycin, cephalothin, lincomycin, and trimethoprim and sulfamethoxazole, chloramphinicol, doxycycline and tetracycline except S. hato. Collapse

2012-02

Al-Mustansiriyah Journal of Science, Univ. of Al-Mustansiriyah Baghdad, Iraq (القضية : 2) (الحجم : 23)

The objective of the current study involved determination chemical composition (including lipid, protein ash, moisture and glycogen) in four fish species from Tigris River in North of Iraq. The chemical analysis revealed that the lipids in muscles of four fish species Carassius carassius, Mastacembleus mastacembleus, Barbas luteus and Silurus triostegus were 8.573 ±0.841 %, 7.715±0.736 %, 8.532± 0.685 %, and 14.650±0.554 % respectively. Proteins content in Carassius carassius, Mastacembleus mastacembleus, Barbas luteus and Silurus triostegus were 310.4 ± ٣.٦٤٩ mg/g, 380.5 ± ٢.٥٣٠ mg/g, 305.1 ± ١.٨٠٠ mg/g and 321.7 ± 3.٥٨٧ mg/g of the fresh weight, respectively. The study also shows that ash content and moisture ranged from 1.55±٠.٠٧٨ and 2.99±٠.٣٦٣ %, 76.05±٠.٥٤٠ and 80.73±٠.١٤٧ % of the fresh weight, correspondingly. The concentrations of protein in the fishes were significantly different among the species. Concentration of protein was the highest in muscle of Mastacembleus mastacembleus and lowest in the muscle of Barbas luteus. The highest concentrations of glycogen was found in the Carassius carassius among the four species (p<0.001).

2011-06

The Iraqi Journal of Veterinary Medicine (القضية : 1609) (الحجم : 35)

Branchiomycosis is a fungal disease that infects fish gills. It was identified by isolation and histopathological changes of examined gills in common carp fish (Cyprinus carpio) which, were obtained from fish farm in Duhok Governorate, Iraq. The infected fish were suffering from respiratory disorders; gulping air at the water surface, rapid movement of operculum and massive mortality, which resulted in the loss of 95% of fish pond. The gills appear marbled appearance with necrotic areas on the localized damage gills. The causal pathogen was identified as Branchiomyces sanguinis, in which the diameter of spores and non-septated hyphae are 5-7 µm and 12 – 20 µm, respectively. In histopathological preparation, the spores and the non-septated hyphae have been shown to be embedded in the gill tissues contained undivided and sporulating stages.

2010-10

Journal of Agriculture and Vet. Medicine/University of Duhok (Iraq).

Isolation of Aeromonas hydrophila from kidneys and livers tissue of common carp (Cyprinus carpio) fish.